PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO), a global healthcare company, today released its financial statement for the period January 1, 2007 to September 30, 2007.
-- Novo Nordisk increased sales by 14% in local currencies and by 9% in
Danish kroner due to a significant negative currency development.
-- Sales of modern insulins increased by 37% (31% in Danish kroner).
-- Sales of NovoSeven(R) increased by 10% (4% in Danish kroner).
-- Sales of Norditropin(R) increased by 12% (7% in Danish kroner).
-- Sales in North America increased by 25% (15% in Danish kroner).
-- Gross margin increased to 76.7% in the first nine months of 2007 up
from 75.2% in the same period last year, primarily reflecting continued
-- Operating profit increased by 11% to USD 1,410 million. Adjusted for
the impact from currencies, underlying operating profit increased by
more than 20%.
-- Net profit increased by 60% to USD 1,361 million, primarily reflecting
the divestment of Dako's business activities in the second quarter of
2007. Earnings per share (diluted) increased by 62% to USD 4.26.
-- The expectation for full-year sales growth is still 11-14% measured in
local currencies and now 6-9% as reported due to the depreciation of
key invoicing currencies. Full-year operating profit growth remains
unchanged around 20% measured in local currencies and is now expected
to be close to 10% as reported.
-- In October, Novo Nordisk received marketing authorization for
Levemir(R) in Japan for both type 1 and type 2 diabetes including
combination treatment with oral antidiabetics.
Lars Rebien Sorensen, president and CEO, said "Our portfolio of modern
insulins continues to show strong sales growth in all key markets. Within
the next few months we
|SOURCE Novo Nordisk|
Copyright©2007 PR Newswire.
All rights reserved